secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2026-08-06T11:05:29+00:00
Accession:  0001104659-26-091619
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports record Q2 revenue ~$99M (+66% YoY); reviewing FY26 guidance; FDA FTD for lifileucel in sarcomas
--------------------------------------------------------------------------------

- Total product revenue ~$99M, up 66% from ~$60M in Q2 2025 and 39% from ~$71M in Q1 2026.
- U.S. Amtagvi revenue ~$91M, up 40% from Q4 2025; gross margin improved to 56%.
- Cash position ~$304M as of June 30, 2026, expected to fund operations into 2H28.
- FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas (UPS/DDLPS); SARATOGA trial ORR 50% in first six patients.
- Australia TGA approved Amtagvi MAA; UK MAA resubmitted for expedited review; FY26 revenue guidance of $350-370M under review.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/0001104659-26-091619-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926091619/tm2622322d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091619

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer